Castle | $1,000,000 | (Jun 27, 2025)
Handspring Health | $12,000,000 | (Jun 27, 2025)
DejaBlue | $8,000,000 | (Jun 27, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Certify | $40,000,000 | (Jun 27, 2025)
Tacta Systems, Inc. | $7,000,000 | (Jun 27, 2025)
Antler Bio | $4,212,546 | (Jun 27, 2025)
Raphe mPhibr | $100,000,000 | (Jun 27, 2025)
DataBahn.ai | $17,000,000 | (Jun 27, 2025)
Klutch AI | $8,000,000 | (Jun 27, 2025)
Niural | $31,000,000 | (Jun 27, 2025)
Jarsy Inc | $5,000,000 | (Jun 27, 2025)
Spekter Games | $5,000,000 | (Jun 27, 2025)